Table 1.
FDA-approved adoptive cell therapies for cancers
| Product | Description | Indication/use | Date approved |
|---|---|---|---|
| Provenge | PAP-GMCSF-activated CD54+ cells | hormone refractory prostate cancer | Apr 29, 2010 |
| Kymriah | CD19-directed CAR-T cells | refractory B cell precursor ALL (pediatric), refractory after two lines of systemic therapy: DLBCL, high-grade BCL | Aug 30, 2017 |
| Yescarta | CD19-directed CAR-T cells | refractory after two lines of systemic therapy: DLBCL, PMLBCL, high-grade BCL | Oct 18, 2017 |
| Tecartus | CD19-directed CAR-T cells | refractory MCL, refractory B cell precursor ALL | Jul 24, 2020 |
| Breyanzi | CD19-directed CAR-T cells | DLBCL, high-grade BCL, PMLBCL, follicular lymphoma grade 3B | Feb 5, 2021 |
| Abecma | BCMA-directed CAR-T cells | relapsed or refractory multiple myeloma | Mar 27, 2021 |
| Carvykti | BCMA-directed CAR-T cells | relapsed or refractory multiple myeloma after four or more prior lines of therapy | Feb 28, 2022 |
DLBCL, diffuse large B cell lymphoma; BCL, B cell lymphoma; PMLBCL, primary mediastinal large B cell lymphoma; ALL, acute lymphoblastic leukemia; MCL, mantle cell lymphoma.